In conclusion, this new MnSOD mimetic Mn1C1A, when associated with oxaliplatin, improves clinical tolerance of oxaliplatin in vivo and prevents oxaliplatin-induced peripheral neuropathy without impairing its antitumoral activity. Here, SOD2 is linked to peripheral neuropathy.